Celanese Announces Engineered Materials Price Increase

DALLAS--(BUSINESS WIRE)-- Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, today announced a price increase for a range of engineered materials products in response to various factors, including recent market developments and global supply chain disruptions.

Despite these dynamic conditions, Celanese remains well positioned to support its customers via its regional supply chain and manufacturing sites, as well as its technology and innovation centers.

The price increases will be effective May 1, 2026, or as contracts otherwise allow. Additionally, individual grades may be subject to higher increases than specified below.

(Applies in addition to the March 13, 2026 price increase announcement for above products.)

About Celanese

Celanese is a global leader in chemistry, producing specialty material solutions used across most major industries and consumer applications. Our businesses use our chemistry, technology and commercial expertise to create value for our customers, employees and shareholders. We support sustainability by responsibly managing the materials we create and growing our portfolio of sustainable products to meet customer and societal demand. We strive to make a positive impact in our communities and to foster inclusivity across our teams. Celanese Corporation is a Fortune 500 company that employs more than 11,000 employees worldwide with 2025 net sales of $9.5 billion.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260417438277/en/

Celanese Contacts:

Investor Relations
Bill Cunningham
+1 972 443 4730
[email protected]

Media Relations – Global
Jamaison Schuler
+1 972 443 4400
[email protected]

Media Relations – Europe
Petra Czugler
+49 69 45009 1206
[email protected]

Source: Celanese Corporation

You May Also Be Interested In

• Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
• Holafly Discount Code TECHREVIEW Unlocks Exclusive Travel eSIM Savings
• Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged P